A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours

被引：0
|
作者：
Hyung-Don Kim
Changhoon Yoo
Min-Hee Ryu
Yoon-Koo Kang
机构：
[1] University of Ulsan College of Medicine,Department of Oncology, Asan Medical Center
来源：
British Journal of Cancer | 2023年 / 129卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：275 / 282
页数：7
相关论文
共 50 条
  • [41] A phase II study of the efficacy and safety of foretinib, a novel receptor tyrosine kinase inhibitor, given on an intermittent 5-days-on/9-days-off (5/9) schedule in patients with recurrent or metastatic squamous cell cancer of the head and neck
    Seiwert, Tanguy
    Swann, Suzanne
    Kurz, Hazel
    Bonate, Peter
    McCallurrt, Stewart
    Sarantopoulos, John
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [42] Early Changes in Cytokines, Chemokines and Indices of Bone Metabolism in a Phase 2 Study of the Bruton Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM)
    Vij, Ravi
    Chang, Betty Y.
    Berdeja, Jesus G.
    Huff, Carol Ann
    Lendvai, Nikoletta
    Tai, Yu-Tzu
    Chang, Stella
    Moussa, Davina
    Buggy, Joseph J.
    Elias, Laurence
    Richardson, Paul G.
    BLOOD, 2012, 120 (21)
  • [43] Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in patients with advanced solid tumors.
    Carden, C. P.
    Kim, E. S.
    Jones, R. L.
    Alam, S. M.
    Johnson, F. M.
    Stephens, A. W.
    Poondru, S.
    Gedrich, R.
    Lippman, S. M.
    Kaye, S. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC)
    Gadgeel, Shirish M.
    Ruckdeschel, John C.
    Heath, Elisabeth I.
    Heilbrun, Lance K.
    Venkatramanamoorthy, Raghu
    Wozniak, Antoinette
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (04) : 299 - 305
  • [45] A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors.
    Marshall, JL
    Lewis, NL
    Amelsberg, A
    Briscoe, J
    Hwang, J
    Malik, S
    Cohen, R
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9072S - 9072S
  • [46] A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors.
    Lewis, N.
    Marshall, J.
    Amelsberg, A.
    Cohen, R. B.
    Stopfer, P.
    Hwang, J.
    Malik, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 143S - 143S
  • [47] A phase I dose escalation study of BIBW 2992, an irreversible tyrosine kinase inhibitor of epidermal growth factor receptor 1 (EGFR-1) and 2 (HER 2) in a 2 week on 2 week off schedule in patients with advanced solid tumors.
    Eskens, FA
    Mom, CH
    Planting, AS
    Gietema, JA
    Aamelsberg, A
    Huisman, H
    Verweij, J
    de Vries, EG
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9023S - 9023S
  • [48] Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/ Refractory Primary Central Nervous System Lymphoma (PCNSL)
    Nagane, Motoo
    Narita, Yoshitaka
    Mishima, Kazuhiko
    Terui, Yasuhito
    Arakawa, Yoshiki
    Yonezawa, Hajime
    Asai, Katsunori
    Fukuhara, Noriko
    Sugiyama, Kazuhiko
    Shinojima, Naoki
    Kitagawa, Junsaku
    Aoi, Arata
    Nishikawa, Ryo
    BLOOD, 2019, 134
  • [49] A Phase 1b/2 Study of Navtemadlin (KRT232), a Murine Double Minute 2 Inhibitor, Combined with a BCR-ABL Tyrosine Kinase Inhibitor in Patients with Relapsed/Refractory, TP53WT, Ph+ Chronic Myeloid Leukemia
    Cortes, Jorge E.
    Jamy, Omer Hassan
    Orti, Guillermo
    Prosper, Felipe
    Grosicki, Sebastian
    Uyei, Anne
    Rothbaum, Wayne P.
    Nicolini, Franck E.
    BLOOD, 2021, 138
  • [50] An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and I in a 4 week on, 2 week off schedule in patients with advanced solid tumors.
    Eskens, F. A.
    Planting, A.
    Van Doorn, L.
    Isoe, T.
    Hayashi, K.
    Hussain, S.
    Ekman, L.
    Burger, H.
    Verweij, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 87S - 87S
12345